Literature DB >> 16343800

Perivascular epithelioid cell sarcoma (malignant PEComa) of the ileum.

A Agaimy1, P H Wünsch.   

Abstract

Epithelioid angiomyolipoma (AML) is the prototype of a heterogeneous group of lesions characterized by the presence of HMB-45 positive cells with clear cytoplasm, perivascular distribution, and combined myomelanocytic features, so-called perivascular epithelioid cells (PECs). These lesions are being increasingly referred to as PEComas. PEComas have been reported at diverse anatomic sites, but mainly in the abdominopelvic cavity and rarely in parenchymatous organs, skin, and soft tissues. Gastrointestinal (GI) PEComas are exceptionally rare, with less than 10 cases documented so far. Rare examples of PEComas with pleomorphic histology could have been misinterpreted as unusual variants of carcinoma or sarcoma. To make a contribution to the differential diagnosis of difficult-to-classify pleomorphic GI sarcomas, we report on a malignant pleomorphic neoplasm with features of PEComa involving the terminal ileum in a 63-year-old woman. Fourteen months after resection of the primary tumor, a huge abdominopelvic recurrence was successfully resected, but no distant metastases were detected. The differential diagnosis and malignancy criteria of GI PEComas will be discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343800     DOI: 10.1016/j.prp.2005.10.008

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  15 in total

1.  Perivascular epithelioid cell neoplasms (PEComas): four malignant cases expanding the histopathological spectrum and a description of a unique finding.

Authors:  Ilan Weinreb; David Howarth; Eleanor Latta; Danny Ghazarian; Runjan Chetty
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

2.  PEComa of the terminal ileum mesentery as a secondary tumour in an adult survivor of embryonal rhabdomyosarcoma.

Authors:  H Hasan; A F Howard; A H Alassiri; T L Ng; G McGregor; K Goddard
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

3.  Long-lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review.

Authors:  Ezequiel Flechter; Yaniv Zohar; Ludmila Guralnik; Maria Passhak; Gil Bar Sela
Journal:  Oncol Lett       Date:  2016-10-06       Impact factor: 2.967

Review 4.  Perivascular epithelioid cell tumor in the duodenum: challenge in differential diagnosis.

Authors:  Zehong Chen; Huijuan Shi; Jianjun Peng; Yujie Yuan; Jianhui Chen; Wu Song
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

5.  A perivascular epithelioid cell tumor of the stomach: an unsuspected diagnosis.

Authors:  Cristina Aparecida Troques da Silveira Mitteldorf; Dario Birolini; Luis Heraldo da Camara-Lopes
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

6.  "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies.

Authors:  Jonathan S Bleeker; J Fernando Quevedo; Andrew L Folpe
Journal:  Sarcoma       Date:  2012-04-26

Review 7.  PEComas: the past, the present and the future.

Authors:  Guido Martignoni; Maurizio Pea; Daniela Reghellin; Giuseppe Zamboni; Franco Bonetti
Journal:  Virchows Arch       Date:  2007-12-14       Impact factor: 4.064

8.  Perivascular epithelioid cell tumor of the ileum presenting as diverticulitis.

Authors:  Saime Unluoglu; Umit Bayol; Nilay Korkmaz; Bekir Ozenen; Fuat Ipekci; Emel Ebru Pala
Journal:  Case Rep Pathol       Date:  2012-04-29

9.  Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor.

Authors:  Constantine Gennatas; Vasiliki Michalaki; Paraskevi Vasilatou Kairi; Agathi Kondi-Paphiti; Dionysios Voros
Journal:  World J Surg Oncol       Date:  2012-09-03       Impact factor: 2.754

10.  Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature.

Authors:  Henry B Armah; Anil V Parwani
Journal:  Diagn Pathol       Date:  2007-12-03       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.